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Introduction
Low cardiac output syndrome (LCOS) 
remains a dreadful complication occurring 
in 5%–15% of patients undergoing 
open‑heart surgery.[1‑4] Systemic 
hypoperfusion results in multiple organ 
dysfunction causing prolonged stay in the 
Intensive Care Unit (ICU) and significant 
postoperative morbidity and mortality.[5] 
Predictors of LCOS have been identified in 
large cohort studies such as advanced age, 
impaired systolic and diastolic ventricular 
function, recent myocardial infarct, renal 
failure, as well as emergent procedures and 
prolonged bypass or aortic cross‑clamping 
times.[6,7]
Nowadays, transesophageal echocardiographic 
examination (TEE) has been widely adopted 
in cardiac surgery, and it has largely 
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Abstract
Introduction: Ventricular dysfunction requiring inotropic support frequently occurs after cardiac 
surgery, and the associated low cardiac output syndrome largely contributes to postoperative 
death. We aimed to study the incidence and potential risk factors of postcardiotomy ventricular 
dysfunction (PCVD) in moderate‑to‑high risk patients scheduled for open‑heart surgery. 
Methods: Over a 5‑year period, we prospectively enrolled 295 consecutive patients undergoing 
valve replacement for severe aortic stenosis or coronary artery bypass surgery who presented with 
Bernstein‑Parsonnet scores >7. The primary outcome was the occurrence of PCVD as defined by 
the need for sustained inotropic drug support and by transesophageal echography. The secondary 
outcomes included in‑hospital mortality and the incidence of any major adverse events as well 
as Intensive Care Unit (ICU) and hospital length of stay. Results: The incidence of PCVD was 
28.4%. Patients with PCVD experienced higher in‑hospital mortality (12.6% vs. 0.6% in patients 
without PCVD) with a higher incidence of cardiopulmonary and renal complications as well as a 
prolonged stay in ICU (median + 2 days). Myocardial infarct occurred more frequently in patients 
with PCVD than in those without PCVD (19 [30.2%] vs. 12 [7.6%]). By logistic regression analysis, 
we identified four independent predictors of PCVD: left ventricular ejection fraction <40% (odds 
ratio [OR] = 6.36; 95% confidence interval [CI], 2.59–15.60), age older than 75 years (OR = 3.35; 
95% CI, 1.64–6.81), prolonged aortic clamping time (OR = 3.72; 95% CI, 1.66–8.36), and 
perioperative bleeding (OR = 2.33; 95% CI, 1.01–5.41). The infusion of glucose‑insulin‑potassium 
was associated with lower risk of PCVD (OR = 0.14; 95% CI, 0.06–0.33). Conclusions: This 
cohort study indicates that age, preoperative ventricular function, myocardial ischemic time, and 
perioperative bleeding are predictors of PCVD which is associated with poor clinical outcome.
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replaced the pulmonary artery catheter in 
evaluating cardiac function and in guiding 
cardiovascular treatments based on a 
more rational physiological approach.[8,9] 
Instead of measuring cardiac output by 
thermodilution, TEE coupled with standard 
hemodynamic monitoring provides the 
unique opportunity to properly diagnose and 
treat hypovolemia, vasoplegic syndrome, 
ischemia‑related dyskinesia, and myocardial 
stunning at the bedside.[10] The term 
“postcardiotomy ventricular dysfunction” 
(PCVD) has been coined to define new 
onset or worsening heart failure that 
requires the administration of inotropes 
and/or mechanical support during the 
weaning period from the cardiopulmonary 
bypass (CPB).[4] Causes of PCVD are 
multifactorial, including surgical tissue 
trauma, myocardial ischemia‑reperfusion 
injuries, downregulation of beta‑adrenergic 
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receptors, coronary embolization (e.g., air, atheroma 
particle), and activation of inflammatory and 
coagulation.[11] The incidence of PCVDs varies from 20% 
to 60% depending on the definition criteria and the case 
mix in cardiac surgical patients.[12,13] Although PCVD can 
be self‑limited – resolving with transient pharmacological 
support – it may also herald a LCOS with its negative 
prognostic clinical implications.[4]
Given its high incidence, identification of patient‑ and 
procedure‑related risk factors of PCVD may represent 
important targets for improving morbidity and mortality 
following cardiac surgery. The purpose of the current 
study was to examine modifiable and nonmodifiable risk 
factors of PCVD in a cohort of moderate‑to‑high risk 
patients undergoing aortic valve replacement (AVR) and/or 
coronary artery bypass surgery (CABG). This prospective 
cohort included all patients who were enrolled in a previous 
randomized control trial that was designed to evaluate 
the safety and cardioprotective effects of the infusion of 
glucose‑insulin‑potassium (GIK) before bypass.
Methods
Patient selection and study design
The cohort included patients with severe aortic valve 
stenosis and/or coronary artery disease who were scheduled 
for elective AVR and/or CABG at the University Hospital 
of Geneva. Eligible patients had a Bernstein‑Parsonnet 
score higher than 7. Exclusion criteria consisted of 
emergent or off‑pump surgery, preoperative critical 
condition, poorly controlled diabetes mellitus, severe 
liver disease (Child‑Pugh C), and dementia or significant 
cerebrovascular disease.
This single‑center trial was approved by the 
Institutional Review Board at the University Hospital of 
Geneva (CER: 08‑095), it was registered on ClinicalTrials.
gov (NCT00788242), and written consent was obtained 
from each eligible participant.
Prospective data were collected according to the checklist 
of the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE).
Perioperative management
The usual medications were continued up to the morning 
of the procedure, except diuretics, antiplatelets, and 
angiotensin‑converting enzyme inhibitors or angiotensin 
II antagonists that were interrupted 1 day before. In the 
operating theater, all patients were equipped with an invasive 
arterial catheter, a central venous line and a bispectral 
monitor (BIS) of the electroencephalogram (Aspect Medical 
Systems A‑2000 XP). Anesthesia management consisted of 
intrathecal morphine (10 mcg/kg), low doses of intravenous 
sufentanil and an infusion of propofol to target BIS values 
between 40 and 60. Cardiac preconditioning was also 
provided with volatile anesthetics (before CPB).
A TEE probe (Matrix Array Probe X7‑2t; Philips 
Medical Systems, Andover, MA, USA) was introduced 
after anesthesia induction, and images were digitally 
acquired before and after CPB and stored with the iE33 
ultrasound imaging system (Philips Medical Systems, 
Andover, MA, USA).[14] Patients were given either the 
GIK solution (human Actrapid, Novo Nordisk 20 IU and 
potassium chloride 10 mEq in 50 ml of 40% glucose) or a 
similar volume of normal saline over 40 min starting after 
the anesthetic induction.
After full heparinization, normothermic CPB was instituted 
with a nonpulsatile flow (2.2–2.5 L/min/m2) and alpha‑stat 
control for acid–base management. The circuit and the 
membrane oxygenator were primed with 2 L of clear 
fluids (1 L Ringer‑Acetate and 1 L of hydroxyethyl starch 
6% 130/0.4). Mean arterial pressure (MAP) was maintained 
between 50 and 70 mmHg with vasoactive medications 
as necessary. During aortic cross‑clamping, myocardial 
protection was achieved by intermittent antegrade infusion 
of cold blood. Antifibrinolytic therapy with tranexamic 
acid was administered before CPB (15 mg/kg intravenous 
over 10 min) and in the CPB priming fluid (10 mg/kg). 
Packed red blood cells were transfused if a hemoglobin 
level <60–65 g/L during CPB or <80–90 g/L after CPB 
was achieved; higher transfusion threshold was set in 
specific groups of patients (e.g., cerebrovascular disease, 
renal dysfunction, or marginal coronary vascularization).
At the end of the procedure, weaning from CPB 
was guided by TEE assessment and hemodynamic 
measurements. After de‑airing the cardiac cavities and 
resumption of mechanical ventilation, the pump flow was 
gradually reduced and the heart was progressively filled. In 
addition to fluid loading, electrical atrioventricular pacing, 
vasopressors, and/or inotropes drugs were given to target 
the following hemodynamic endpoints: left ventricular (LV) 
end‑diastolic diameter between 2.2 and 2.8 cm/m2, MAP 
between 65 and 100 mmHg, and heart rate between 
70 and 100 beats/min. Two cardiothoracic anesthesiologists 
with extensive experience were directly involved in the 
perioperative management of each case and adhered to the 
institutional written guidelines [Figure 1].[15]
Study endpoints
In this STROBE compliant descriptive cohort study, 
we collected all data related to patient demographic 
and physical status, comorbidities, current medications, 
anesthetic and surgical management, as well as 
postoperative cardiac outcome during the primary 
hospitalization. These data were reported on a case report 
form and entered in an electronic database.
The diagnostic criteria of PCVD – the primary study 
endpoint – was the need for inotropic support for more 
than 120 min (dobutamine >5 mcg/kg/min, epinephrine 
>0.05 mcg/kg/min, milrinone >0.3 mcg/kg/min, and 
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norepinephrine >0.04 mcg/kg/min) in the presence of 
impaired ventricular function and a low MAP (<60 mmHg) 
despite adequate circulatory filling. Other causes of low 
arterial pressure such as hypovolemia and vasoplegic 
syndrome were excluded since these conditions could 
be corrected with fluid loading and vasopressor therapy, 
respectively.
As secondary clinical endpoints, we reported in‑hospital 
mortality and the incidence of cardiovascular adverse events 
(myocardial infarct, atrial fibrillation, LCOS, and stroke), 
respiratory complications (atelectasis, pneumonia, and 
mechanical ventilation >24 h), renal dysfunction (reduction 
in estimated glomerular filtration >25%), re‑operation, 
perioperative bleeding (requirement for >4 packed red 
blood cell transfusion), and the length of stay in the ICU 
and until hospital discharge. A modified version of the 
Dindo‑Clavien systemic classification was used to report 
major adverse events [Annex A].[16]
Statistical analysis
Perioperative clinical and surgical characteristics as 
well as postoperative outcome data of patients with and 
without PCVD were compared with the Chi‑square test 
for categorical variables (expressed in percentage) and 
the Student’s t‑test (normal distribution) or Wilcoxon 
rank test (non‑Gaussian distribution) for continuous 
variables (all expressed as mean ± standard deviation).
Variables that had a univariate P < 0.15 or those judged 
to be clinically important were selected for inclusion in a 
logistic regression model by stepwise forward selection. 
Only one variable in a set of variables with a correlation 
coefficient >0.5 was retained to avoid multicollinearity. 
Figure 1: A standardized approach for weaning from bypass
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Independent predictors of PCVD and factor‑adjusted odds 
ratios (ORs) with 95% confidence interval (CI) were 
calculated. All analyses were performed using STATA 14 
software (Stata Corp., College Station, TX, USA) and 
statistical significance was specified as a two‑tailed Type I 
error (P value) set below the 0.05 level.
Results
Over a 5‑year period, 295 moderate‑to‑high risk patients 
were screened, 243 provided informed consent, 21 were 
excluded (study staff unavailable, n = 7; not meeting 
selection criteria, n = 14), and 222 with completed 
data were analyzed. In this cohort, 141 patients (64%) 
received intravenous inotropic drug support and 
26 (12%) required assistance with an intra‑aortic balloon 
pump counterpulsation. The criteria of PCVD were 
met in 63 patients (28.4%). Compared with the group 
without PCVD, patients with PCVD were significantly 
older, presented more often signs of heart failure and 
higher Parsonnet scores, had longer CPB and aortic 
clamping times, and received less frequently GIK before 
CPB [Table 1]. Other clinical and surgical data were 
similar in the two groups.
Of the 28 preoperative and intraoperative variables 
subjected to univariate analysis, nine demonstrated a 
significant association with the occurrence of PCVD: 
age older than 75 years, low body mass index, low LV 
ejection fraction (LVEF), elevated Parsonnet score, renal 
dysfunction, perioperative bleeding, a long bypass time 
or aortic clamping time, and the administration of GIK 
[Table 2]. A significant correlation was found between aortic 
clamping time and CPB time (R2 = 0.731) and therefore 
only aortic clamping time was considered into the logistic 
regression model. Likewise, the Bernstein‑Parsonnet score 
was not included in the model to avoid multicollinearity.
Logistic regression analysis identified five independent 
predictors of PCVD [Table 3]: prebypass GIK (OR = 0.14; 
95% CI, 0.06–0.33), LVEF <40% (OR = 6.36; 95% 
CI, 2.59–15.60), age older than 75 years (OR = 3.35; 95% 
CI, 1.64–6.81), prolonged clamping time (OR = 3.72; 95% 
CI, 1.66–8.36), and perioperative bleeding (OR = 2.33; 
95% CI, 1.01–5.41). This multivariate model for predicting 
LV dysfunction was accurate, with an area under the 
receiver operating characteristic curve of 0.81 and a 
Hosmer‑Lemeshow goodness‑of‑fit value of 0.91 indicating 
good model calibration. There was no evidence that 
additional covariates would improve the model (P = 0.539 
by the likelihood‑ratio test).
Postoperative outcome data are shown in Table 4. 
Compared with patients without PCVD, those experiencing 
PCVD presented higher in‑hospital mortality (12.7% 
vs. 0.6%, P < 0.001) with increased incidences of 
cardiovascular and respiratory complications as well as 
renal dysfunction. Noteworthy, among patients with PCVD, 
myocardial infarct developed more frequently (19 [30.2%] 
vs. 12 [7.6%] in patients without PCVD) as well as a 
LCOS (24 [38.1%] vs. 11 [6.9%]). Furthermore, the need 
for prolonged mechanical ventilation and the ICU and 
hospital length of stay were significantly higher in patients 
with PCVD.
Discussion
In this cohort including moderate‑to‑high‑risk patients 
scheduled for open heart surgery, 28% of them experienced 
PCVD and these patients had a prolonged stay in the ICU 
owing to more frequent cardiopulmonary complications and 
renal dysfunction compared with patients without PCVD. 
Advanced age, preoperative low LVEF, perioperative 
bleeding, and prolonged aortic clamping time were all 
identified as independent risk factors of PCVD whereas the 
administration of GIK before bypass was associated with 
myocardial protection.
The elevated risk profile of this cohort was mainly related 
to advanced age (63% ≥70 years) and a high prevalence 
of some comorbidities (hypertension in 93% of patients, 
LVEF <50% in 65%, diabetes mellitus in 28%, and chronic 
obstructive lung disease in 14%). According to a mean 
Parsonnet score of 21, the overall predicted mortality was 
5.5%[17] and the lower observed mortality (4.0%) could 
partly be attributed to the perioperative protocol‑driven 
approach where the anesthetic and surgical techniques 
were standardized and a goal‑directed protocol based on 
TEE and hemodynamic monitoring was applied to separate 
patients from CPB.
In the current trial, the main study endpoint –PCVD – was 
clearly defined as the need for prolonged pharmacological 
inotropic support and was helpful to identify patients at 
risk for adverse postoperative clinical outcome. Weaning 
the patient from the CPB remains a critical phase where 
both the cardiac surgeon and the anesthesiologist share 
important information regarding the completeness of 
surgery and postischemic functional recovery of the 
heart. Within a short time, important decisions are taken 
regarding additional surgical interventions in case of 
ongoing myocardial ischemia, paravalvular regurgitation, 
or valve prosthesis mismatch.[18] Likewise, cardiovascular 
drugs are selectively prescribed and titrated to support the 
failing heart and to correct the vasoplegic syndrome that 
often occurs after myocardial ischemia‑reperfusion.[10]
Although PCVD most often resolved within the first 
hours after surgery, in 30% of our surgical cases, 
PCVD forecasted the development of LCOS and it 
was associated with myocardial infarction and/or 
ischemia‑reperfusion injuries as evidence by a larger 
release of cardiac troponin. The consequent mismatch 
between oxygen supply and metabolic requirements was 
also manifested by decreased glomerular filtration rate 
and impaired respiratory muscle function along with a 
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prolonged need for mechanical ventilation and a higher 
propensity for pulmonary complications. Moreover, the 
perioperative use of inotropes could further contribute 
to worsen postoperative clinical outcome as reported 
in several large cohort studies where inotrope therapy 
has been identified as a risk factor of postoperative 
mortality and cardiovascular complications.[19‑21] Indeed, 
catecholamines may transiently enhance postischemic 
functional recovery and accelerate weaning from 
bypass; however, by promoting insulin resistance and 
fatty acid oxidation (instead of glucose utilization), the 
administration of catecholamines increases myocardial 
Table 1: Baseline preoperative and intraoperative characteristics of patients undergoing open cardiac surgery and 
presenting or not postcardiotomy ventricular dysfunction
Preoperative All (n=222) PCVD (n=63) No PCVD (n=159) P
Demographic and clinical data
Age (years)* 71.3 (10.7) 74.3 (10.1) 70.1 (10.7) <0.001†
Weight (kg)* 79.9 (14.7) 78.8 (15.4) 80.4 (14.4) 0.472†
Height (cm)* 169.4 (8.6) 170.1 (8.8) 169.1 (8.5) 0.446†
Body mass index* 27.9 (5.0) 27.3 (5.5) 28.1 (4.7) 0.281†
Sex (male) 153 (68.9) 43 (68.3) 110 (69.0) 0.893
Hypertension 206 (92.8) 59 (93.7) 147 (92.5) 0.756
Pulmonary hypertension 22 (9.9) 10 (15.9) 12 (7.6) 0.061
Diabetes mellitus 84 (37.8) 25 (39.7) 59 (37.1) 0.721
Vascular disease 93 (41.9) 25 (39.7) 68 (42.8) 0.674
Chronic obstructive lung disease 31 (14.0) 7 (11.1) 24 (15.1) 0.440
Karnofsky performance status <50 25 (11.3) 9 (14.3) 16 (10.1) 0.370
Previous cardiac surgery 15 (6.8) 1 (1.6) 14 (8.8) 0.053
NYHA class‡ 2 (2‑3) 2 (2‑4) 2 (2‑3) 0.041§
LVEF (%)* 45.0 (9.6) 41.9 (11.2) 46.3 (6.9) 0.003†
Parsonnet score* 21.2 (8.3) 24.0 (7.6) 20.0 (8.4) 0.001†
Chronic preoperative medications
Beta‑blockers 114 (51.4) 34 (54.0) 80 (80.3) 0.623
Calcium antagonists 28 (12.6) 6 (9.5) 22 (13.8) 0.383
ACEI or angiotensin‑II blocker 102 (46.0) 23 (36.5) 79 (49.7) 0.076
Diuretics 76 (34.2) 26 (41.3) 50 (31.5) 0.164
Anti‑platelets 148 (66.7) 38 (60.3) 110 (69.2) 0.207
Blood parameters
Hemoglobin (g/dL)* 12.2 (2.1) 11.9 (2.2) 12.3 (2.0) 0.211†
Creatinine clearance (mL/min)* 92.8 (39.9) 84.9 (40.2) 95.9 (39.5) 0.067†
Intraoperative All (n=222) PCVD (n=63) No PCVD (n=159) P
Type of surgery
Aortic valve replacement 107 (48.2) 30 (47.6) 77 (48.4) 0.913
Coronary artery bypass graft 81 (36.5) 33 (33.3) 60 (37.7) 0.539
Combined 34 (15.3) 12 (19.1) 22 (13.8) 0.331
Surgical time
CPB time (min)* 108.5 (46.5) 128.2 (55.6) 100.7 (40.1) <0.001†
Aortic clamping time (min)* 77.1 (34.4) 89.1 (38.6) 72.4 (31.6) 0.001†
Fluids
Crystalloids (mL)* 2808 (1090) 3017 (1106) 2725 (1075) 0.072
Crystalloids (mL/min)* 12.5 (5.1) 12.2 (5.5) 12.6 (4.9) 0.628
Colloids (ml)* 280 (452) 298 (477) 273 (442) 0.702
Colloids (mL/min)* 1.1 (1.8) 1.1 (2.1) 1.1 (1.8) 0.905
Blood transfusion 148 (66.7) 41 (65.1) 107 (67.3) 0.752
Fresh frozen plasma 65 (29.3) 22 (34.9) 43 (27.0) 0.245
Platelets 36 (16.2) 13 (20.6) 23 (14.5) 0.261
GIK before CPB 110 (50.0) 18 (28.6) 92 (57.9) <0.001
Data given as n (%) unless otherwise indicated. Chi‑squared tests were used for statistical tests unless otherwise indicated. *Data 
given as mean (SD), †Student’s t‑test, ‡Data given as median (range), §Wilcoxon rank‑sum test. ACEI: Angiotensin converting enzyme 
inhibitor, CPB: Cardiopulmonary bypass, PCVD: Postcardiotomy ventricular dysfunction, NYHA: New York Heart Association, 
GIK: Glucose‑insulin‑potassium, LVEF: Left ventricular ejection fraction, SD: Standard deviation
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Table 2: Effect of patient characteristics and perioperative management on the occurrence of postcardiotomy 
ventricular dysfunction
Preoperative patient characteristics PCVD OR 95% CI P
Yes, n (%) No, n (%)
Age >75 (years)
Yes 38 (40.4) 56 (59.6) 2.80 1.51‑5.19 <0.001
No 25 (19.5) 103 (80.5) 1.00 Reference ‑
Body mass index
>21‑30 40 (28.2) 102 (71.8) 1.00 Reference ‑
>30 18 (25.0) 54 (75.0) 0.85 0.44‑1.93 0.623
≤21 5 (62.5) 3 (37.5) 4.22 0.94‑19.12 0.040
Sex
Male 43 (28.1) 110 (71.9) 1.00 Reference ‑
Female 20 (29.0) 49 (71.0) 1.04 0.56‑1.96 0.893
High blood pressure
Yes 59 (28.6) 147 (71.4) 1.20 0.37‑3.90 0.756
No 4 (25.0) 12 (75.0) 1.00 Reference ‑
Pulmonary hypertension
Yes 10 (45.5) 12 (54.6) 2.31 0.93‑5.71 0.062
No 53 (26.5) 147 (73.5) 1.00 Reference ‑
Diabetes
Yes 25 (29.8) 59 (70.2) 1.12 0.61‑2.03 0.722
No 38 (27.5) 100 (72.5) 1.00 Reference ‑
Vascular disease
Yes 25 (26.9) 68 (73.1) 0.88 0.49‑1.60 0.675
No 38 (29.5) 91 (70.5) 1.00 Reference ‑
Chronic obstructive lung disease
Yes 7 (22.6) 24 (77.4) 0.70 0.29‑1.73 0.441
No 56 (29.3) 135 (70.7) 1.00 Reference ‑
Karnofsky performance status <50
yes 9 (36.0) 16 (64.0) 1.49 1.69‑3.58 0.371
No 54 (27.4) 143 (72.6) 1.00 Reference ‑
Parsonnet score >22
Yes 40 (40.8) 58 (59.2) 3.03 1.62‑5.67 <0.001
No 23 (18.6) 101 (81.5) 1.00 Reference ‑
LVEF <40%
Yes 25 (51.0) 23 (49.0) 3.70 1.85‑7.40 <0.001
No 38 (22.0) 135 (78.0) 1.00 Reference ‑
NYHA class ≥3#
Yes 22 (36.7) 38 (63.3) 1.71 0.90‑3.24 0.096
No 41 (25.3) 121 (74.7) 1.00 Reference ‑
Anemia (Hb <100g/l)
Yes 12 (42.9) 16 (57.1) 2.10 0.92‑4.78 0.070
No 51 (26.3) 143 (73.7) 1.00 Reference ‑
Renal insufficiency (eGFR <60)
Yes 18 (41.9) 25 (58.1) 2.14 1.06‑4.33 0.029
No 45 (25.1) 134 (74.9) 1.00 Reference ‑
Chronic preoperative medications
Beta‑blockers
Yes 34 (29.8) 80 (70.2) 1.16 0.64‑2.08 0.624
No 29 (26.9) 79 (73.2) 1.00 Reference ‑
Calcium antagonists
Yes 6 (21.4) 22 (78.6) 0.66 0.25‑1.71 0.384
No 57 (29.4) 137 (70.6) 1.00 Reference ‑
Contd...
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Table 2: Contd...
Preoperative patient characteristics PCVD OR 95% CI P
Yes, n (%) No, n (%)
ACEI or angiotensin‑II blocker
Yes 23 (22.6) 79 (77.5) 0.58 0.32‑1.07 0.076
No 40 (33.3) 80 (66.7) 1.00 Reference ‑
Diuretics
Yes 26 (34.2) 50 (65.8) 1.53 0.83‑2.81 0.165
No 37 (25.3) 109 (74.7) 1.00 Reference ‑
Anti‑platelets
Yes 38 (25.7) 110 (74.3) 0.68 0.37‑1.25 0.201
No 25 (33.8) 49 (66.2) 1.00 Reference ‑
Surgical and intraoperative characteristics PCVD OR 95% CI P
Yes, n (%) No, n (%)
Type of surgery
CABG 21 (25.9) 60 (74.1) 1.00 Reference ‑
AVR 30 (28.0) 77 (72.0) 1.11 0.58‑3.13 0.747
Combined 12 (35.3) 22 (64.7) 1.56 0.66‑3.69 0.313
Previous cardiac surgery
Yes 1 (36.0) 14 (64.0) 0.17 0.02‑1.33 0.054
No 62 (27.4) 145 (72.6) 1.00 Reference ‑
Bleeding
Yes 16 (42.1) 22 (57.9) 2.12 1.02‑4.41 0.040
No 47 (25.5) 137 (74.5) 1.00 Reference ‑
Long aortic clamping time*
Yes 24 (45.3) 29 (54.7) 2.76 1.42‑5.36 <0.001
No 39 (23.1) 130 (76.9) 1.00 Reference ‑
Long CBP time**
Yes 23 (43.4) 30 (56.6) 2.42 1.26‑4.79 0.006
No 40 (23.7) 129 (76.3) 1.00 Reference ‑
Prebypass GIK
Yes 18 (16.4) 92 (83.6) 0.29 0.15‑0.56 <0.001
No 45 (40.2) 67 (59.8) 1.00 Reference ‑
Blood transfusion
Yes 41 (27.7) 107 (72.3) 0.91 0.49‑1.68 0.753
No 22 (29.7) 52 (70.3) 1.00 Reference ‑
Fresh frozen plasma
Yes 22 (33.9) 43 (66.2) 1.45 0.77‑2.71 0.246
No 41 (26.1) 116 (73.9) 1.00 Reference ‑
Platelets
Yes 13 (36.1) 23 (63.9) 1.54 0.72‑3.28 0.262
No 50 (26.9) 136 (73.1) 1.00 Reference ‑
Fluids (>12.5 mL/min)
Yes 26 (23.4) 85 (76.6) 0.61 0.34‑1.11 0.102
No 37 (33.3) 74 (66.7) 1.00 Reference ‑
*>75 percentile stratified for surgery: CABG >80 min, AVR >96 min; combined >120 min, **>75 percentile stratified for surgery: 
CABG >120 min, AVR >127 min; combined >160 min. ACEI: Angiotensin‑converting enzyme inhibitors, eGFR: Estimated glomerular 
filtration rate, Hb: Hemoglobin, NYHA: New York Heart Association functional classification of heart failure, CABG: Coronary artery 
bypass graft, AVR: Aortic valve replacement, CPB: Cardiopulmonary bypass, PCVD: Postcardiotomy ventricular dysfunction, OR: Odds 
ratio, CI: Confidence interval, GIK: Glucose‑insulin‑potassium, LVEF: Left ventricular ejection fraction
oxygen consumption and deplete energetic substrates 
within the cardiomyocytes.[22] Consequently, short‑term 
hemodynamic improvement can be outweighed by adverse 
events related to arrhythmias, hyperglycemia, lactic 
acidosis, and beta‑adrenergic receptor desensitization.
The risk factors for PCVD in the current study were 
similar to those reported for LCOS in previous studies,[3,6,23] 
and this emphasizes the clinical and pathophysiological 
continuum between these two entities. Preoperative risks 
factors such as advanced age and low LVEF are not 
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amenable to optimization therapies. Experimental evidence 
supports that the senescent hearts are more vulnerable 
to ischemic insults while being also more refractory to 
protective interventions.[24] Likewise, in patients with 
low LVEF, the wide range in myocardial viability due 
to remodeling and fibrotic changes results in a greater 
propensity to ischemia‑reperfusion injuries.[25] Importantly, 
these “non‑modifiable” factors are also included in the 
popular risk scoring systems (e.g., EuroScore, Parsonnet, 
Society of Thoracic Surgery) as risk factors to predict 
mortality after cardiac surgery and therefore might be 
useful to select the surgical candidates and to rationalize 
resources utilization in the hospital.[17,26]
It is worth mentioning that these current risk classification 
systems do not consider the intraoperative time course 
which can be a decisive factor for the postoperative 
patient’s clinical outcome.[27] In the present trial, we 
found that the duration of aortic cross‑clamping and 
perioperative bleeding were predictors of PCVD. 
Interestingly, these intraoperative factors can be modified 
by implementing dedicated protocols and by improving 
the expertise, the skills and experience of the heart 
team. Aortic cross‑clamping time reflects ischemic injury 
and despite modern myocardial protection techniques, 
it remains a prominent mechanism leading to LCOS 
regardless of the preoperative LVEF.[28‑30] Noteworthy, 
prolonged aortic clamping times and perioperative 
bleeding may also denote technical difficulties in executing 
the planned operation because of unfavorable anatomy 
or intraoperative complications. Besides perioperative 
bleeding, preoperative anemia and low hematocrit during 
CPB have also been identified as modifiable risk factors 
of postoperative mortality, renal failure and cardiovascular 
morbidity.[31]
These intraoperative factors are closely related since 
both CPB and myocardial ischemia‑reperfusion trigger 
a systemic inflammatory response manifested by a 
hyperdynamic circulatory state, alteration in platelet 
Table 3: Logistic regression analysis showing the 
adjusted odds ratios for variables independently 
associated with the occurrence of postcardiotomy 
ventricular dysfunction
Adjusted OR 95% CI P #
GIK 0.14 0.06‑0.33 <0.001
LVEF <40% 6.36 2.59‑15.60 <0.001
Age >75 (years) 3.35 1.64‑6.81 <0.001
Prolonged aortic 
cross‑clamping*
3.72 1.66‑8.36 <0.001
Perioperative bleeding 2.33 1.01‑5.41 0.048
*>75 percentile stratified for surgery: CABG >80 min, AVR >96 min; 
combined >120 min, #Wald test. CI: Confidence interval, OR: Odds 
ratio, CABG: Coronary artery bypass surgery, AVR: Aortic valve 
replacement, GIK: Glucose‑insulin‑potassium, LVEF: Left ventricular 
ejection fraction
Table 4: Outcome of patients with and without postcardiotomy ventricular dysfunction
Outcome All (n=222) PCVD (n=63) No PCVD (n=159) P
Mortality 9 (4.5) 8 (12.7) 1 (0.6) <0.001°
AVR 2 (1.9) 2 (6.7) 0 0.077°
CABG 3 (3.7) 3 (14.3) 0 0.016°
Combined surgery 4 (11.8) 3 (25.0) 1 (4.6) 0.115°
Cardiovascular complications
Atrial fibrillation 98 (44.1) 34 (54.0) 64 (40.3) 0.064
Low cardiac output syndrome 35 (15.8) 24 (38.1) 11 (6.9) <0.001
Myocardial infarct 31 (14.0) 19 (30.2) 12 (7.6) <0.001
Stroke 10 (4.5) 2 (3.2) 8 (5.0) 0.729
Troponin I (day 1) (µg/L)‡ 3.4 (1.8‑6.4) 5.3 (3.0‑14.3) 3.1 (1.6‑5.8) <0.001§
Respiratory complications
Atelectasis 76 (34.2) 31 (49.2) 45 (28.3) <0.001
Pneumonia 20 (9.0) 13 (20.6) 7 (4.4) <0.001
Ventilation >24 h 95 (42.8) 44 (69.8) 51 (32.1) <0.001
Renal dysfunction
Reduction in GFR >25% 44 (19.8) 20 (31.8) 24 (15.1) 0.005
Surgical complications
Bleeding 38 (17.1) 16 (25.4) 22 (13.8) 0.039
Need for redo surgery 17 (7.7) 7 (6.3) 10 (11.1) 0.771
Length of stay (days)
ICU‡ 3 (2‑5) 5 (3‑11) 3 (2‑4) <0.001§
Hospital‡ 15 (12‑21) 20 (15‑27) 14 (11‑17) <0.001§
Data given as n (%) unless otherwise indicated. Chi‑squared tests were used for statistical tests unless otherwise indicated. ‡Data given as 
median (range), §Wilcoxon rank sum test, °Fisher’s exact test. PCVD: Postcardiotomy ventricular dysfunction, CABG: Coronary artery bypass 
surgery, AVR: Aortic valve replacement, GFR: Glomerular filtration rate, ICU: Intensive Care Unit
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function and coagulation factors, activation of leucocytes 
and endothelial cells, as well as the release of cytokines 
and oxygen free radicals.[11] Therefore, prolonged duration 
of CPB and aortic cross‑clamping has been associated not 
only with PCVD but also with more frequent pulmonary 
complications, larger requirement for transfusion, and 
renal impairment.[28] Besides standard anterograde blood 
cardioplegia, the implementation of GIK before CPB 
was associated with a marked attenuation of the PCVD, 
supporting the growing body of scientific knowledge on 
GIK‑induced myocardial protection.[32,33] The enhanced 
postischemic ventricular function could be attributed to 
the higher glycogen stores as the energetic pathway can be 
switched from fatty acids to glucose oxidation when the 
GIK metabolic cocktail is given before ischemia.[34,35]
There are some limitations in our study. First, our study 
remains retrospective despite the fact that all data were 
prospectively collected, and as such, we can only report 
on associations rather than causality between the PCVD 
and the reported risk factors. Second, potential risk factors 
such as preoperative renal dysfunction, frailty or functional 
dependency, diabetes, vascular disease, or prior cardiac 
surgery could not be analyzed given the relatively small 
sample size of the study population and the low prevalence 
of some comorbidities. Likewise, patients with severe organ 
failure were excluded and exploring the impact of critical 
concomitant illnesses would deserve larger cohorts with a 
wider range of pathologies. Finally, the limitations related 
to this single‑center study, its retrospective design, and the 
small sample preclude generalizability of our results.
Conclusions
Our data indicate that age, duration of aortic cross‑clamping, 
and preexisting LV systolic dysfunction are independent 
risk factors for early PCVD whereas the administration 
of GIK is association with a lower incidence of PCVD in 
moderate‑to‑high risk patients undergoing AVR or coronary 
artery bypass graft surgery. These data strengthen the 
need for randomized controlled trials testing perioperative 
management strategies aimed to target modifiable risk 
factors in patients undergoing cardiac surgery.
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Annex A: Modified classification system of postoperative complications*
Cardiovascular Pulmonary Renal Others
Grade I: Transient, 
self‑limiting AE
Nonsustained arrhythmias
Hypotension associated with anesthesia 
induction or mild hypovolemia
Mild hypoxemia responsive 
to O2 therapy (<0.3 FiO2)
<25% decrease in 
eGFR
Grade II: AE requiring 
pharmacologic treatment or 
minor intervention
Arrhythmias requiring pharmacologic 
treatment
Hypotension associated with mild 
hypovolemia
Moderate hypoxemia, 
atelectasis requiring CPAP 
support
Superficial SSI
Grade IIIa: AE event requiring 
intervention without sedation/
general anesthesia or 
potentially causing disability
Arrhythmias requiring electrical 
cardioversion
Hypovolemia requiring aggressive fluid 
management
Myocardial ischemia
Transient cerebral ischemia
Atelectasis requiring 
bronchoscopy or intense 
chest therapy
Moderate‑severe 
Hypoxemia requiring NIV 
support
Pneumonia
25%‑50% 
decrease in eGFR
Deep SSI
Grade IIIb: AE requiring 
intervention under sedation/
general anesthesia or causing 
disability
Myocardial infarct (mild)
Stroke
New or worsening heart failure, LCOS 
requiring pharmacological support (1 
drug)
Severe hypoxemia requiring 
NIV support (ALI/ARDS, 
pneumonia, heart failure, 
muscle failure)
>50% decrease in 
eGFR
Mediastinitis
Grade IVa: Admission in ICU 
for single organ dysfunction
New or worsening heart failure, LCOS 
requiring intense pharmacological 
support (>2 drugs) and/or mechanical 
assistance
Recurrent or sustained arrhythmias
Myocardial ischemia/infarct (extensive)
Severe hypoxemia requiring 
intubation and mechanical 
ventilator support (ALI/
ARDS, pneumonia, heart 
failure, muscle failure)
Renal failure 
requiring 
hemodialysis or 
hemofiltration
Grade IVb Cardiac arrest with resuscitation Combined organ 
dysfunction
SSI: Surgical site infection, AE: Adverse event, eGFR: Estimated glomerular filtration rate, CPAP: Continuous positive airway pressure, 
NIV: Noninvasive ventilation, ALI: Acute lung injury, ARDS: Acute respiratory distress syndrome, LCOS: Low cardiac output syndrome
